




# CINP

THE INTERNATIONAL COLLEGE OF  
NEUROPSYCHOPHARMACOLOGY

**Biennial  
Business  
Report  
2020 – 2022**

# Table of Contents

<b>President's Report</b>	<b>3</b>
<b>Treasurer's Report</b>	<b>5</b>
<b>Secretary's Report</b>	<b>6</b>
<b>Nominations Committee Report</b>	<b>7</b>
<b>Credential and Membership Committee Report</b>	<b>8</b>
<b>CINP 2022 Awardees</b>	
Pioneer Awards	<b>9</b>
Sumitomo/Sunovion Brain Health Basic Research Award	<b>11</b>
Sumitomo/Sunovion Brain Health Clinical Research Award	<b>11</b>
Ethics Prize	<b>12</b>
Max Hamilton Award	<b>12</b>
Rafaelsen Awards	<b>13</b>
Student Awards - Supported by Meiji Seika Pharma	<b>14</b>
<b>Editor-in-Chief Report</b>	<b>15</b>



# President's Report

## Pierre Blier, MD, PhD



My term as CINP President is coming to an end and I would like to report to you, the members of CINP, on our achievements and progress as a society during my term as President of the college as well as the future plans for the coming years. I took over the leadership of this society in February 2021 due

to the extension of Prof. Kasper's presidency, resulting from the postponement of the 2020 congress. This decision to extend the mandate of the Executive (EC) from June 2020 to February was an unanimous one due to the postponing of the 2020 because of the pandemic. I would like to express my gratitude to Professor Kasper once more for his dedication to CINP and the insights he provided during his extended term as President as well as after his term as Past President. As Professor Siegfried Kasper will now be leaving the EC after 10 years of service, I wish him all the best in the future.

Despite the ongoing changes and uncertain future facing CINP at the beginning of my presidency, it was clear to me that certain key initiatives needed to continue unimpeded. Namely, to ensure the long-term financial viability of the college while looking for solutions to the upcoming challenges. Below is a summary of what I feel have been our key accomplishments.

### A. CINP Management and Governance

As the international society to promote the study, teaching, and application of neuropsychopharmacology, the crucial work of CINP requires thousands of hours of effort behind the scenes each year by volunteers and our professional staff.

#### 1. Pure dedication by the board and office.

After one year of hard work and dedication by International Conference Services (ICS) staff as well as the CINP Board, the society was yet again challenged by the ongoing COVID-19 pandemic. CINP's first-ever Virtual World Congress in 2021 was a great success and would not have been possible without the foresight and judgement of our EC and the hard work of our support staff. In order to make this possible, we did have to make the difficult decision to again postpone the World Congress in Montréal, Canada, to May 2023. Shortly thereafter, we focused our attention on the 2022 World Congress rescheduled for Taipei. Based on our learned

experience with the 2021 virtual congress and Taipei's ongoing travel restrictions, we made the decision to host a hybrid World Congress in 2022. This would allow those members of our community who are able to attend in person in Taipei to do so, while still providing access to our world-class content and insights to virtual attendees remotely. As we continue to navigate uncertain waters, we have been very well served by our staff team, including Association Director Matt Riley, Association Manager Yannik Braemer, Congress Manager Gertrud Jeewanjee, and the rest of the congress team, who focus on marketing, registration, sponsorship, virtual video production, and technology support.

#### 2. Contract negotiations with OUP.

The collaboration with OUP is continuously being advanced since 2017 and we are very happy about the close relationship the society enjoys with its publisher. The International Journal of Neuropsychopharmacology has reached an impact factor of more than 5 last year and therefore marked an important milestone. Thanks to the dedication of former Editor-in-Chief Alan Frazer as well as our current Editor-in-Chief Anthony Grace and his editorial board, the EC is confident that the journal will further contribute to the science by publishing breakthrough articles in our field. We would like to ensure a stable foundation for the work of the editorial board, which is why we seek to extend our contract with OUP for another term. The CINP office and EC is currently in the final phase of the contract negotiations and hope to report on the contract extension in the next month.

#### 3. Automatic membership renewal.

We always seek improvement on the technological side to ensure that your CINP membership is both as valuable and as convenient as possible. In addition to other improvements, I am also delighted to announce that since January 2022, CINP Members & Fellows are now able to automatically renew their membership on January 1 of each year by saving their credit card details securely in their membership profiles at CINP.org. If you would like to save yourself the trouble of manually renewing each year, please feel free to log into your own CINP membership account to activate the new feature. As always, if you have any questions, we are ready to help you at [info@cinp.org](mailto:info@cinp.org).

#### 4. Best practice - proposals for management services.

In 2019, CINP hired International Conference Services (ICS) to manage both the society and congress for the following 5 years. Even though we have been very happy with the services provided by ICS in the past 4 years, we as the EC



# President's Report

deemed that it is best practice for every organization to seek proposals for management services when approaching the end of a contract. This ensures competitive pricing and proper management of CINP's resources. In collaboration with an external consultant, the EC has asked several international companies for their proposals that are currently being collected and reviewed. Before the end of the year, the Executive Committee will make a decision regarding how to proceed with the society's management beginning in 2023.

## B. CINP Objectives

Beyond managing its day-to-day operations and governance, CINP has important scientific and administrative goals that serve our greater mission. I would like to highlight a few areas of continuing focus for the society:

### 1. Fostering the global scientific community

The annual CINP World Congress is still the main pillar in terms of our activities and represents the most important way for the neuropsychopharmacology community to share new research findings, learn about new developments, and build friendships and collaborations around the world. However, as we have seen all too clearly over the past several years, in person events can be subject to disruption, and it is important for CINP to pursue other ways of meeting this goal as well. In addition to supporting and collaborating with well-established regional partner societies including ACNP, AsCNP, and ECNP, CINP is also committed to providing educational events and opportunities to developing nations.

Furthermore, we are also supporting the next scientific generation by closely collaborating with the European Federation of Psychiatric Trainees (EFPT). The CINP Education Committee chaired by Prof. Joseph Zohar organized several online webinars together with the EFPT in order to share the latest developments in the field with younger scientists. We would like to further follow this path and seek new ways of supporting the next generation of neuropsychopharmacology minds. Eventually, we hope that our financial efforts will ultimately generate additional funding that we can devote to this important work.

### 2. Encouraging diversity in neuropsychopharmacology

Studies have shown that diversity of backgrounds can help to balance biases, ensure that questions are considered from every angle, and ultimately result in better outcomes. For that reason and many others, I am proud of CINP's commitment to promote diversity in terms of race, age, gender, sexual orientation, disability, philosophical and religious beliefs,

cultural background, health status, and language. Not only the CINP Diversity Task Force contributed to an increasing diversity among the CINP membership, but also a gender balance on Executive Committee and Council ensures increased engagement by our members. Furthermore, all EC members speak a different language other than English, which is another diversity pillar of which I am proud.

## C. Expressions of gratitude and congratulations

In addition to those that I thanked earlier, I would like to thank my fellow CINP members for giving me the opportunity to lead this wonderful society. I would also like to thank the staff of our office for their valuable assistance throughout my term. Additionally, I would like to thank the members of the Executive Committee, including Past President Siegfried Kasper, President-Elect Joseph Zohar, Vice Presidents Shih-Ku Lin and Maria Oquendo, Treasurer Kazutaka Ikeda, and Secretary Gabriella Gobbi as well as our ten CINP Councilors, who all continuously supported me during my presidency. Furthermore, I would like to congratulate Kazutaka Ikeda for his election as incoming President Elect, Dan Rujescu on becoming CINP Vice President as well as Ming-Chyi Huang on becoming CINP Treasurer. I would also like to congratulate Hilary Blumberg, Atsumi Nitta, Julio Licinio, Kristina Adorjan, Ya-Mei Bai, Hiroyuki Uchida and Kim Do on joining the board as Councilor for the term 2022-2026. I will be also honored to remain on the EC as Immediate Past President.

I have greatly enjoyed my time as CINP President and feel very confident to pass the role on to such an experienced and accomplished leader as Joseph Zohar. I congratulate the CINP members for their high degree of participation in this election. As I look back on the challenges we have met and future ones facing us, I foresee continued success and great things ahead for CINP in line with those achieved since its inception in 1957.

Sincerely,



### Pierre Blier

MD, PhD

CINP President (2021-2022)



# Treasurer's Report

## Prof. Kazutaka Ikeda, Japan



My four-year term as CINP Treasurer has come to an end, and it has been a pleasure and an honor to serve CINP in this role. Although the pandemic required a large degree of agility from a financial perspective, I believe that together with the Executive Committee, the Finance & Budget Committee, and our management

company ICS, we were able to steer the ship through these difficult times successfully and to ensure the long-term financial stability of the CINP.

While the decision to move the 2020 congress to 2021 and change the format to virtual was a difficult undertaking, from a financial perspective we believe strongly that this was the right decision. The overall profit from the congress ensured a positive financial outcome in 2021. As we carefully plan and closely monitor the progress of both the 2022 Hybrid World Congress and the 2023 in-person congress in Montreal, we believe that these events will deliver strong profitability for the society. This in turn will allow us to cover our operating expenses and to begin to regrow the financial reserves which we needed to draw down during the early phases of the pandemic.

Even though membership income slightly decreased in 2021, we are confident that we will generate more than \$60,000 in membership dues revenue in 2022, partially due to the high interest in the hybrid congress, which helps to drive new member enrollments. We are also trying to find new ways to generate additional income to be able to host more educational events. With the annual World Congress which would normally take place without a pandemic, additional income will be generated which allows CINP to further contribute to the field of neuropsychopharmacology. I would also like to report on the current funds of CINP which are split into our bank account as well as investments. The bank account currently holds \$170,000 and our investment value is currently at \$1,430,000 which results in total funds of \$1,600,000.

Lastly, I would like to express my gratitude to our CINP Head Office staff for their assistance during the last two years, managing the financial side of things within the college efficiently and effectively. I would also like to thank Fiona Struthers from AD+ for her role in auditing the financial activities of the society and providing excellent advice on how we manage risk. Finally,

I would like to thank CINP President Prof. Pierre Blier and the members of EC and the Finance and Budget Committee for their fruitful collaboration.

Below you will find the tentative 2021 accounts which have been prepared together with the CINP Head Office. Please note that these figures are currently being reviewed by our auditors, and as such there could be some minor changes in the final, audited accounts.

I have very much enjoyed my time as CINP Treasurer and I look forward to continuing to serve as CINP President-Elect, President as well as Past President over the next six years. I am also confident that the incoming Treasurer, Ming-Chyi Huang, will prove to be an excellent successor for this position who will fulfill the duties with the utmost diligence. I will be working closely together with her during her four-year term in order to ensure the long-term financial viability of the college and to continue its important contributions to the field of neuropsychopharmacology.

	2020 Funds	2021 Projected Funds*
<b>Projected Income &amp; Endowments</b>		
<b>Charitable Activities</b>		
Membership Dues	\$58,152	\$53,938
Congress Profit	-	\$178,108
Journal Income	\$64,372	\$111,198
<b>Total Income</b>	<b>\$122,524</b>	<b>\$343,244</b>
<b>Projected Expenditure</b>		
<b>Charitable Activities</b>		
Charitable Expenditure	\$395,690	\$318,383
<b>Total Expenditure</b>	<b>\$395,690</b>	<b>\$318,383</b>
<b>Projected Net incoming / (outgoing) resources</b>	<b>(\$273,166)</b>	<b>\$24,861</b>

\*2021 Projected Funds subject to audit

# Secretary's Report

## Dr. Gabriella Gobbi, Canada



In the past, most of the meetings of the CINP Executive Committee (EC) were conducted in-person, generally four times per year. However, this has changed with the ongoing pandemic. Between the Virtual Congress in February 2021 and today, the EC met twelve times. One meeting before the ACNP Annual

Meeting in December 2021 took place in a hybrid format as some EC members and staff attended the meeting while others decided to join virtually. Under the leadership of the CINP President, Dr P. Blier, the committee met regularly and together with the expertise of our management company, International Conference Services Ltd. (ICS), we safeguarded CINP through these difficult times. During the almost monthly meetings, we continuously monitored the COVID situation and discussed other key decisions regarding the college, including how to proceed with the 2022 CINP World Congress, which led to this congress being transformed into the 2022 Hybrid World Congress in Taipei.

Among other items discussed were the contract negotiations with Oxford University Press for the publishing of the International Journal of Neuropsychopharmacology (IJNP), plans to increase CINP membership income, venues for future World Congresses, the 2022 elections for the available positions on the Executive Committee and Council, and the selection of recipients for the various CINP awards.

One important development within the college was a strong increase in engagement from several Asian countries in form of new members, council members as well as high attendance at the World Congresses and educational activities. In order to further ensure the diversity of among our currently 604 members building the membership and leadership, we would like to also empower people of all genders from other parts of the world including Africa and South America to join the conversation. Additionally, our diversity should continue to improve as we rotate our annual World Congress between the various continents. From a scientific perspective, it will also be important to make these congresses attractive for active researchers wanting to exchange views and recent data as well for clinicians wanting an update in relevant fields of neuropsychopharmacology. Given the increasing need of continuous learning and the

ongoing expansion of knowledge in clinical psychiatry and neuroscience, the CINP should make an effort in the coming years to find novel strategies to enhance its platform for teaching neuropsychopharmacology and clinical psychiatry even in non-developed countries.

Another key element of CINP's member value are the opportunities to network and the access to science for young researchers. We continuously look for opportunities inside and outside of CINP to advance the future of our field and its most promising future leaders. Specific sessions for young scientists at our World Congress, a close collaboration between the CINP Education Committee and the European Federation of Psychiatric Trainees (EFPT), and other online and offline events all contribute to the common goal of giving a platform to the next generation of this important field of study.

I have found the first two years of my four-year term as CINP Secretary very rewarding and am very much looking forward to working with the other Executive Committee members until the 2024 World Congress in Tokyo, Japan while taking steps to continue the progress mentioned above.

# Nominations Committee Report

By Committee Chair

**Prof. Siegfried Kasper**



I would like to sincerely thank the members of this committee for their support in selecting the slate of candidates for key CINP leadership positions over the last two years. In 2022, there were three vacant positions on the Executive Committee (President-Elect, Vice President & Treasurer) as well as seven positions on the CINP Council.

## Committee Members

- Carol Tamminga, USA
- Gustavo Turecki, Canada
- Peter Falkai, Germany
- Shih-Ku Lin, Taiwan

Nominations for each position were submitted by members and reviewed by the Committee. We took into consideration knowledge of CINP, contribution to CINP, diversity, geographical spread, and scientific interests. After careful consideration by the Committee members, a slate of candidates was presented to the Executive Committee and finalized. Finally, all fully paid CINP Members and Fellows were invited to vote for a candidate for each position.

The online voting by the membership went smoothly as 78.5% of the in total 382 eligible voters voted. On behalf of the Nominating Committee, I hereby would like to present the names of those elected by the membership:

**President-Elect (2022 – 2024):** Kazutaka Ikeda, Japan (M)  
(President 2024 – 2026;  
Past-President 2026 – 2028)

**Vice President (2022 – 2026):** Dan Rujescu, Austria (M)  
**Treasurer (2022-2026):** Ming-Chyi Huang, Taiwan (F)  
**Councilors (2022 – 2026):** Julio Licinio, USA (M)  
Kristina Adorjan, Germany (F)  
Ya-Mei Bai, Taiwan (F)  
Hiroyuki Uchida, Japan (M)  
Kim Do, Switzerland (F)  
Atsumi Nitta, Japan (F)  
Hilary Blumberg, USA (F)

Together with the new additions to the CINP Board, the new CINP Executive Committee and new Council consist of the following members:

## CINP Executive Committee

- Joseph Zohar, Israel (President, M)
- Pierre Blier, Canada (Past President, M)
- Kazutaka Ikeda, Japan (President-Elect, M)
- Maria Oquendo, USA (Vice President, F)
- Dan Rujescu, Austria (Vice President, M)
- Ming-Chyi Huang, Taiwan (Treasurer, F)
- Gabriella Gobbi, Canada (Secretary, F)

## CINP Council

- Atsumi Nitta, Japan (F)
- Carlos Zarate, USA (M)
- Hilary Blumberg, USA (F)
- Hiroyuki Uchida, Japan (M)
- Julio Licinio, USA (M)
- Kim Do, Switzerland (F)
- Kristina Adorjan, Germany (F)
- Noboru Hiroi, USA (M)
- Tian Mei Si, China (F)
- Ya-Mei Bai, Taiwan (F)

With the newly elected officers we were able to improve the geographical as well as gender balance within the CINP Board. There are now three female members on the Executive Committee as well as six female members out of ten members on the Council.

I would like to take this opportunity to thank the members of the Nominating Committee for their support, the Executive Committee for their advice, the CINP Central Office for carrying out the online voting and communications, and especially the CINP members who actively participated in the nomination and election process.

# Credentials And Membership Report

By Committee Chair

**Prof. Kazutaka Ikeda**



The CINP membership has continued to grow in the past two years again as 107 new members joined the college over the course of 2020 and 2021. The wide distribution of members across the world as well as the increasing diversity of our membership underline that CINP is a truly global society.

I would like to sincerely thank the members of this committee for their support in the past years who worked diligently to promote the advantages of CINP membership all over the globe.

- Allan Young, UK
- Elias Eriksson, Sweden
- Gabriella Gobbi, Canada
- Jun Soo Kwon, Korea
- Lucie Bartova, Austria
- Yasumasa Okamoto, Japan

Below you can find an overview of the countries of our new members and their membership level over the course of 2020 and 2021.

New Members by Country				New Members by Category	
United States	25	Sweden	2	Members	56
Japan	14	Cambodia	1	Fellows	27
Taiwan	9	Chile	1	Associate Members	24
Canada	8	Greece	1		
Austria	4	Indonesia	1		
India	4	Israel	1		
United Kingdom	4	Netherlands	1		
Australia	3	Norway	1		
China	3	Peru	1		
Italy	3	Republic of Korea	1		
Russia	3	Saudi Arabia	1		
Switzerland	3	South Africa	1		
France	2	Spain	1		
Germany	2	Thailand	1		
Hong Kong	2	United Arab Emirates	1		
Singapore	2			<b>Total</b>	<b>107</b>

# CINP 2022 Awardees

## Pioneer Awards



**Tomas Hökfelt**  
Sweden

Tomas Hökfelt is a student of Nils Åke Hillarp, who together with Bengt Falck and Arvid Carlsson developed the formaldehyde fluorescence method for visualizing dopamine, noradrenaline and serotonin in

a fluorescence microscope. Hökfelt in his thesis described the localization of these monoamine systems in the brain and periphery at the ultrastructural level, i.e. in the electron microscope. He then went on to identify GABA neurons in the brain using autoradiography. In collaboration with Menek Goldstein and Kjell Fuxe he used immunohistochemistry and antibodies to the catecholamine-synthesizing enzymes to re-analyze the monoamine systems - and discovered the brain adrenaline neurons. Using the same method he mapped the neuropeptides in the nervous system and found that this large family of peptide transmitters coexists in neurons also expressing classic transmitters, like monoamines and amino acids. He then studied the functional role of neuropeptides, in particular in pain and depression/depression like behavior. A special focus has been the 29/30 amino acid neuropeptide galanin and its three receptors GalR1-3. This work was then expanded from rodents to humans and includes both genetic analysis and studies of postmortem brains from depressed subjects who committed suicide. Hökfelt has suggested that targeting the galanin system with appropriate ligands can cause both pain relief and induce antidepressant effects.



**Nancy Andreasen**  
USA

Nancy C. Andreasen, M.D., Ph.D., is Andrew H. Woods Chair of Psychiatry at The University of Iowa College of Medicine. She is actively involved in neuroimaging research, which involves the use of structural MR imaging,

functional MR, and positron emission tomography. In addition, she leads a team working on three-dimensional image analysis techniques to integrate multi-modality imaging and to develop innovative methods for analyzing structural and functional imaging techniques in an automated manner. She has been given a Research Scientist Award from NIMH for her work in this area, directs a Mental Health Clinical Research Center and a training program that emphasizes neuroimaging, and conducts several investigator initiated projects in the area. Dr. Andreasen is past president of the American Psychopathological Association and the Psychiatric Research Society, as well as a member of the Institute of Medicine and the American Academy of Arts and Sciences. She won the President's National Medal of Science for 2000. She has received the American Psychiatric Association Prize for Research and the Dean Award from The American College of Psychiatrists, as well as the Distinguished Service Award of the latter organization. Dr. Andreasen is Editor-in-Chief of The American Journal of Psychiatry. She has written a book on neuroimaging (Brain Imaging: Applications in Psychiatry), as well as more than 500 articles and seven books on other related topics. Title of Research: The primary emphasis of her research is on the development and application of novel neuroimaging tools, the study of normal cognition and emotion, and the study of major mental illnesses such as schizophrenia, schizophrenia spectrum disorders, schizoaffective disorder, schizophreniform disorder, and schizotypal personality.

# CINP 2022 Awardees

## Pioneer Awards (ctd.)



**Toshitaka Nabeshima**  
Japan

Professor Nabeshima has graduated Master Course of Graduate School of Pharmaceutical Sciences, Osaka University, in 1970. He has received Ph.D. from Tohoku University in 1977.

He has worked as Assistant Professor and Associate Professor at Faculty of Pharmaceutical Sciences, Meijo University from 1973 to 1989. During this time, he has joined Professor I.K. Ho as Research Consultant (July 1983 - September 1983); Research Associate (March 1982 - April 1982); Visiting Assistant Professor (July 1980 - April 1981); Visiting Instructor (November 1978 - June 1980) at University of Mississippi Medical Center, U.S.A.

He has become Professor and Director at Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine in 1990. He has moved to Faculty of Pharmaceutical Sciences, Meijo University as Professor in 2007 and chaired until 2012. After retirement, he has developed as Designated Professor, Department of Regional Pharmaceutical Care & Sciences, Faculty of Pharmacy, Meijo University (2012 - 2015). From December 2015, he is working at Fujita Health University as Visiting Professor.

He has received many awards such as CINP2021 Pioneer Award, JSNP Special Achievement Award (2014), ASHP Donald E. Franke Medal (2008), Professor Emeritus of Nagoya University (2007) & Univ. Al. I. Cuza, din Iasi, Romania (1999) and so on.

He has published more than 900 papers. He has developed 38 Professors and 16 Associate Professor. He has developed many animal models for Alzheimer disease, Schizophrenia, Depression, ADHD etc. to investigate the mechanism of onset and evaluate new drugs.

# CINP 2022 Awardees

## Sumitomo/Sunovion Brain Health Basic Research Award



**Gabriella Gobbi**  
Canada

Gabriella Gobbi, MD, PhD and Psychiatrist is a Professor in the Department of Psychiatry, McGill University and holds the Canada Research Chair in Therapeutics for Mental Health (Tier 1).

Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research.

Dr Gobbi's lab is interested in understanding the pathophysiology of mental diseases and over the years discovered new treatments and cures for them.

i) Her laboratory demonstrated in animal models and in humans that the long term use of cannabis in adolescence can lead to depression later in life.

ii) Her lab also discovered and patented novel selective agonists of the melatonin MT1 and MT2 receptors for treating pain, insomnia, and anxiety. One of these drugs is reaching the IND status.

iii) More recently, she published and patented research unveiling the mechanism of action of LSD and psychedelics in social anxiety and post-stress anxiety.

Dr. Gobbi is author of more than 120 highly cited manuscripts in high impact journals, 20 book chapters, one book, and inventor of international patents in psychopharmacology.

Trilingual speaker, she has been invited to present her work at conferences around the world and has served as reviewer/ editor for many journals, international grant agencies in Europe and USA.

Dr Gobbi served as an expert witness for the Canadian Senate (2012), the Ministry of Health (2019) and the Ministry of Justice (2019) of Quebec for the cannabis legislation, her studies on cannabis have influenced policies raising the age of cannabis consumption from 18 to 21 yo in Quebec and banning the advertisement of cannabis.

## Sumitomo/Sunovion Brain Health Clinical Research Award



**Celso Arango**  
Spain

Professor Celso Arango is currently Chair of the Child and Adolescent Department of Psychiatry at Hospital General Universitario Gregorio Marañón, Complutense University in Madrid, Spain, as well as Director

of the Gregorio Marañón Psychiatric and Mental Health Institute, Professor of Psychiatry at the Maryland Psychiatric Research Center of the University of Maryland in Baltimore, Adjunct Professor of Psychiatry at UCSF in San Francisco, Visiting Professor of Psychiatry at Kings College London, and Tenured Full Professor at Complutense University in Madrid.

Dr. Arango leads one of the few research groups in the world focusing on early-onset psychosis with the largest cohort of pediatric first psychotic episode patients. He has transitioned to the field of early intervention and has created an innovative intervention program for first-episode patients and their families (PIENSA). The program was validated in a RCT and exported to various universities in Europe and the US. He has lobbied for the creation of early intervention services in Spain, resulting in recent successful examples of new services created for this population.

Professor Arango was the first Scientific Director of the Spanish Psychiatric Research Network (CIBERSAM) with 24 centers and more than 400 researchers, from its creation in 2008 until 2017. The CIBERSAM coordinated the roadmap for mental health research for the European Commission. He has participated in more than 76 competitively funded research projects and in 13 EU-funded projects.

He has written more than 675 peer-reviewed articles and 11 books and is on the editorial board for 20 national and international journals.

# CINP 2022 Awardees

## Ethics Prize



**Laura Roberts**  
USA

Dr. Laura Roberts serves as Chairman and the Katharine Dexter McCormick and Stanley McCormick Memorial Professor in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of

Medicine as well as serves in a number of leadership roles at Stanford University and in the Stanford Medicine enterprise. She is a physician-scientist in academic medicine and an internationally recognized scholar in bioethics, psychiatry, medicine, and medical education. Dr. Roberts' early work elevated the perspectives of key stakeholders in psychiatric research, engaging with individuals with lived experience of mental and physical disorders, investigators, community members, and policymakers. Over two decades, Dr. Roberts has received scientific, peer-reviewed funding from the National Institutes of Health and Department of Energy, as well as private foundations to perform empirical studies of modern ethical issues in research, clinical care, and health policy, with a particular focus on vulnerable and special populations.

Dr. Roberts has written hundreds of peer-reviewed articles and other scholarly works, and she has written or edited many books in the areas of professionalism and ethics in medicine, professional development for physicians, and major texts in clinical psychiatry. Dr. Roberts is the Editor-in-Chief of the journal *Academic Medicine* and has served as Editor-in-Chief, *Books for the American Psychiatric Association* since 2016. Dr. Roberts also served as the Editor-in-Chief for the journal *Academic Psychiatry* from 2002-2019 and she also serves as an editorial board member and peer reviewer for many scientific and education journals.

Having received her Bachelor of Arts in History and Master of Arts in the Conceptual Foundations of Science from the University of Chicago, she completed her medical degree and a fellowship in clinical medical ethics at the University of Chicago Pritzker School of Medicine. Dr. Roberts completed her residency training in psychiatry at the University of New Mexico School of Medicine, where she also received additional clinical preparation in child and adolescent

psychiatry. Dr. Roberts served on the faculty of the University of New Mexico School of Medicine for nine years, performing evidence-based ethics research, administration, education, and clinical work in the specialized area of consultation-liaison psychiatry. While serving as Professor and Vice Chairman for her Department, Dr. Roberts established the University of New Mexico Institute for Ethics and was appointed the Jack and Donna Rust Professor of Biomedical Ethics prior to her departure in 2003. She then moved to the Medical College of Wisconsin, where for seven years she served as chairman of the Department of Psychiatry and the Charles E. Kubly Professor of Psychiatry and Behavioral Medicine.

## Max Hamilton Award



**Robert McCutcheon**  
United Kingdom

Dr McCutcheon completed a BSc In Chemistry before studying medicine at University College London. He commenced research in psychopharmacology while an academic foundation trainee at the University Oxford, before

coming to the Maudsley to undertake specialist clinical training in psychiatry. He joined the Institute of Psychiatry, Psychology & Neuroscience's department of Psychosis Studies in 2013, and here undertook a PhD in multimodal neuroimaging. His current research attempts to develop novel treatments for mental illness by investigating how largescale patterns of brain activity are influenced by molecular processes.

# CINP 2022 Awardees

## Rafaelsen Awards



**Miriam Schiele**  
Germany

Dr. Miriam Schiele is a senior researcher and assistant professor at the Department of Psychiatry and Psychotherapy, University of Freiburg. After completing her studies in psychology, she obtained her

PhD at the University of Wuerzburg, Germany. As head of the research groups “Experimental Psychiatry and Psychotherapy” and “Obsessive-Compulsive Disorders”, Dr. Schiele’s research focus is on identifying multi-level markers for the prediction, prevention and personalized treatment of anxiety disorders, mood disorders and obsessive-compulsive disorder as well as on investigating the mechanisms of action mediating therapy response, particularly by applying patho- and therapy-epigenetic approaches.



**Jennifer Phillips**  
Canada

Dr. Jennifer Phillips is a Scientist at University of Ottawa Institute of Mental Health Research in Ottawa, Canada. She is also the Director of Research and an Assistant Professor in the Department of Psychiatry at

the University of Ottawa and an Adjunct Research Professor in the Department of Neuroscience at Carleton University. Dr. Phillips received her BSc from Brock University and her PhD in Neuroscience from the University of Ottawa. Dr. Phillips’ expertise is in clinical neuroscience with a focus on depression and suicide prevention. Dr. Phillips’ ongoing studies investigate the biological underpinnings of depression and suicidal behaviour using magnetic resonance imaging (MRI) and peripheral biomarkers, and test the efficacy of ketamine to treat depression in patients resistant to other forms of treatment.



**Sameer Jauhar**  
United Kingdom

Dr. Jauhar graduated in Medicine from Glasgow University in 2002, having also completed a degree in Public Health and Epidemiology.

He moved to the Institute of Psychiatry in 2012, to work with Oliver Howes and Shitij Kapur on predominantly PET studies of the dopamine system, with the focus on psychosis and treatment response.

His research interests focus on understanding neurobiological causes of psychotic illness, with a focus on the affective psychoses.

Further interests pertain to psychopharmacological treatment of psychotic and affective illnesses, and evidence-based psychiatry.

He has received travel awards/grants from the European Psychiatric Association, European Congress of Neuropsychopharmacology, British Association for Psychopharmacology, and Schizophrenia International Research Society.

He received a Royal College of Physicians, Edinburgh JMS Sim Fellowship in 2018, enabling him to build on work examining the presynaptic dopamine system in affective psychoses. In 2019 he received the Senior Clinical Award from the British Association for Psychopharmacology.

Clinically, he has worked as a Consultant Psychiatrist in Early Intervention in Psychosis since 2012, throughout South London and Maudsley NHS Trust.

# CINP 2022 Awardees

## Student Award - Supported by Meiji Seika Pharma



**Hajime Miyanishi**  
Japan



**Peter Stoehrmann**  
Austria



**Yukiko Ochiai**  
Japan



**Patricia Anna Handschuh**  
Austria



**Giuseppe Fanelli**  
Italy



**Chih-Ming Cheng**  
Taiwan

# Editor-in-Chief Report

## Anthony A. Grace



I am pleased to present an update of the activities of the IJNP in 2021-2022. In July of 2020 I became the Editor-in-Chief of the journal, following in the footsteps of Alan Frazer, who did an outstanding job as the previous Editor-in-Chief. After a brief dip due to the move to Open Access, I am pleased to share that our Impact Factor has

increased from 4.207 to 5.176. We expect this to increase further as the number of quality submissions increases. For instance, we are receiving a higher proportion of clinical manuscripts, which tend to be cited more often.

We currently have 50 members on our editorial board and, appropriately for an international journal, there is a broad geographical distribution: 23 from Europe; 18 from North America; 3 from Asia and Australia, and 6 from South America.

We had a virtual Field Editors' retreat in September 2021, where we announced changes in makeup of our Field Editors and Editorial Board. We changed from 7 Field Editors to 5 Field Editors to better manage our budget and to distribute the workload more equitably. Also, due to the increase in clinical papers and the presence of multiple molecular techniques in each contribution type, we have added an additional clinical Field Editor in place of our prior genetics Field Editor. In addition, Gitte Knudsen has resigned as imaging Field Editor due to other responsibilities and has been replaced by Romina Misrahi. This gives us a gender balance of 2 females and 3 males, with the following two Field Editors being added:

- Joshua Kantrowitz (Clinical)
- Romina Misrahi (Imaging)

### Two previous Field Editors ended their role:

- David Goldman (previously Genetics/Molecular Field Editor)
- Gitte Knudsen (previously Imaging Field Editor)

Regarding the Editorial Board, in order to fill out expertise in needed areas and for various other reasons, two members on the board will no longer serve in that role:

- Francesc Artigas
- Andrea Giuffrida

This provides us with a total membership of 50, with 22 Female Members: (44%). We will have a virtual Editorial Board meeting in the early Summer of 2022

### Geographical distribution of submissions (2021):

Europe – 49  
North America – 42  
South America – 4  
Australia – 2  
Asia – 73  
Middle East – 8  
Africa – 7

### Geographical distribution of accepted manuscripts (2021):

Europe – 32  
North America – 30  
South America – 4  
Australia – 1  
Asia – 20  
Middle East – 1  
Africa – 2

Full text HTML and PDF article downloads have continued to increase, increasing from a monthly average of 57,294 and 65,229 YTD in 2022.

In order to disseminate information regarding the broadening scope of our journal and to attract more high-impact papers in areas such as neurology, we recently added a tagline that has been implemented and added to our cover: Translational Research into Brain Function and Disease. This is currently included on our journal web page as well.

We chose the two most cited basic and clinical articles for 2020-2021. This was very difficult in some instances given that the top 4 most cited were all clinical, but the selected articles were:

### Clinical

Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial Direct Current Stimulation in Neurological and Psychiatric Disorders

Fregni, Felipe; El-Hagrassy, Mirret M.; Pacheco-Barrios, Kevin; Carvalho, Sandra; Leite, Jorge; Simis, Marcel; Brunelin, Jerome; Nakamura-Palacios, Ester Miyuki; Marangolo, Paola; Venkatasubramanian, Ganesan; San-Juan, Daniel; Caumo, Wolnei; Bikson, Marom; Brunoni, Andre R.

10.1093/ijnp/pyaa051

50 citations

# Editor-in-Chief Report

## Preclinical

Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/Caspase-1/GSDMD Pathway in MPTP-Induced Mice Model of Parkinson's Disease

Rui, Wenjuan; Li, Sheng; Xiao, Hong; Xiao, Ming; Shi, Jingping

10.1093/ijnp/pyaa060

20 citations

Another piece of good news is that the Journal continues to contribute significant revenue to the College. Total journal revenue for the journal in 2021 was GBP 177,653; at 25% royalty share this is a total GBP 44,413 due to CINP.

In addition to the Editorial Board members, I would like to take the opportunity to thank the many people who make the production of IJNP possible, in particular the Field Editors, my Editorial Assistant, Ann Miller, and Sara Yanny-Tillar, who manage the Journal for Oxford University Press (OUP), and the entire marketing and production team at OUP. I would also like to thank the CINP Head Office staff, who manage the finances of the Journal, and who recently led a contract renegotiation process that will further increase CINP's journal revenues by more than \$150,000 over the next five years.

#CINP2023



34<sup>th</sup> CINP World Congress  
of Neuropsychopharmacology  
7-10 May 2023 Montreal, Canada

**SAVE THE DATE**





## **CINP Head Office**

Kirchgasse 48  
8024 Zurich  
Switzerland

Phone: +43 660 1258 463  
Fax: +1 604 681 1049  
info@cinp.org | [www.cinp.org](http://www.cinp.org)

For further information on CINP and to keep up to date with all CINP activities, please visit [www.cinp.org](http://www.cinp.org).